NDA 211150 · Harmony
Wakix
Pitolisant Hydrochloride · Oral
Breakthrough therapyPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Feb 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Oct 13, 2020
Approved uses
4
Original approval plus efficacy supplements
Registered trials
36
20 Phase 3, 4 recruiting
FAERS reports
2,117
1,013 serious, 10 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 13, 2026.
WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) or cataplexy in patients 6 years of age and older with narcolepsy. WAKIX is a histamine-3 (H3) receptor antagonist/inverse agonist indicated for the treatment of excessive daytime sleepiness (EDS) or cataplexy patients 6 years of age and older with narcolepsy ( 1 )
Mechanism: The mechanism of action of pitolisant in excessive daytime sleepiness (EDS) or cataplexy in patients 6 years and older with narcolepsy is unclear. However, its efficacy could be mediated through its activity as an antagonist/inverse agonist at histamine-3 (H3) receptors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 13, 2026 Supplement 6 · Efficacy · priority review OrphanLetterLabel
- Jun 21, 2024 Supplement 5 · Efficacy · priority review OrphanLabelLetter
- Oct 13, 2020 Original approval · Efficacy · priority review OrphanLabelLetterReview
- Aug 14, 2019 Original approval · Type 1 - New Molecular Entity · priority review Breakthrough therapyOrphanLabelLetterReview
2 products under this application
- WAKIX · PITOLISANT HYDROCHLORIDE EQ 4.45MG BASE · TABLET, ORAL · Prescription · TE AB
- WAKIX · PITOLISANT HYDROCHLORIDE EQ 17.8MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Pitolisant" as an intervention, any sponsor and status, largest first.
- Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSAPivotal-lookingCompleted
BioprojetAcademic, hospital or other
NCT02739568 · 389 participants · Start Apr 2016 · Primary completion Apr 2020
Drug: Pitolisant (BF2.649); Placebo · For: Excessive Daytime Sleepiness; Obstructive Sleep Apnea
Sites: Burgas, Bulgaria; Kozloduy, Bulgaria; Pleven, Bulgaria · 6 sites in all
- Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's DiseasePivotal-lookingCompleted
BioprojetAcademic, hospital or other
NCT01066442 · 273 participants · Start Mar 2010 · Primary completion Aug 2012
Drug: BF2.649 (Pitolisant) · For: Parkinson's Disease
Sites: Marburg, Germany
- BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP.Pivotal-lookingCompleted
BioprojetAcademic, hospital or other
NCT01072968 · 268 participants · Start Oct 2011 · Primary completion May 2014
Drug: BF2.649; Placebo · For: Obstructive Sleep Apnea; Excessive Daytime Sleepiness
Sites: Grenoble, France
- Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's DiseasePivotal-lookingCompleted
BioprojetAcademic, hospital or other
NCT01036139 · 268 participants · Start Dec 2009 · Primary completion Aug 2012
Drug: BF2.649 (pitolisant) · For: Parkinson's Disease
Sites: Paris, France
- A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With NarcolepsyPivotal-lookingRecruiting
Harmony Biosciences Management, Inc.Industry
NCT07675135 · 258 participants (planned) · Start Jun 4, 2026 · Primary completion Oct 2027
Drug: HBS-301 · For: EDS; Cataplexy; Fatigue and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Peoria, Arizona · 64 sites in all
- A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)Pivotal-lookingRecruiting
Harmony Biosciences Management, Inc.Industry
NCT07500090 · 248 participants (planned) · Start Mar 16, 2026 · Primary completion Oct 2027
Drug: HBS-301 tablet; Placebo · For: Idiopathic Hypersomnia
Sites: Birmingham, Alabama; Mobile, Alabama; Peoria, Arizona · 54 sites in all
- BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDSPivotal-lookingCompleted
BioprojetAcademic, hospital or other
NCT01071876 · 244 participants · Start Aug 2011 · Primary completion Mar 2014
Drug: BF2.649; Placebo · For: Obstructive Sleep Apnea; Excessive Daytime Sleepiness
Sites: Grenoble, France
- A Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of EDS in Patients With OSAPivotal-lookingCompleted
Citrine Medicine LimitedIndustry
NCT05223166 · 240 participants · Start Apr 12, 2022 · Primary completion Jul 18, 2023
Drug: Pitolisant; Placebo oral tablet · For: Excessive Daytime Sleepiness
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea245
- drug ineffective239
- anxiety235
- headache222
- insomnia221
- product administration interrupted203
- somnolence190
- product dose omission issue186
- fatigue184
- dizziness125
- middle insomnia125
- depression116
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 7 |
| 2016 | 17 |
| 2017 | 7 |
| 2018 | 20 |
| 2019 | 39 |
| 2020 | 496 |
| 2021 | 158 |
| 2022 | 240 |
| 2023 | 294 |
| 2024 | 444 |
| 2025 | 272 |
| 2026 | 123 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Wakix (Pitolisant HCl)
2024 spending
$132M
Beneficiaries
1,402
10,596 claims
Per beneficiary
$94,477
$248.34 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $31,542,408 |
| 2021 | $55,827,154 |
| 2022 | $65,551,787 |
| 2023 | $101,374,313 |
| 2024 | $132,456,458 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline.
Maski K, Trotti LM, Kotagal S, et al. · J Clin Sleep Med 2021 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.
Dauvilliers Y, Bassetti C, Lammers GJ, et al. · Lancet Neurol 2013 · Comparative Study, Multicenter Study
- Pitolisant for treating patients with narcolepsy.
Li S, Yang J · Expert Rev Clin Pharmacol 2020 · Systematic Review
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.
Maski K, Trotti LM, Kotagal S, et al. · J Clin Sleep Med 2021 · Meta-Analysis, Research Support, N.I.H., Extramural
- Evaluating pitolisant as a narcolepsy treatment option.
de Biase S, Pellitteri G, Gigli GL, et al. · Expert Opin Pharmacother 2021 · Comparative Study, Systematic Review
- Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial.
Dauvilliers Y, Lecendreux M, Lammers GJ, et al. · Lancet Neurol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Harmony
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.